"Valproic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.
| Descriptor ID |
D014635
|
| MeSH Number(s) |
D02.241.081.944.509.900 D10.251.400.895.593.900
|
| Concept/Terms |
Valproic Acid- Valproic Acid
- Propylisopropylacetic Acid
- 2-Propylpentanoic Acid
- 2 Propylpentanoic Acid
- Divalproex
Divalproex Sodium- Divalproex Sodium
- Semisodium Valproate
- Valproic Acid, Sodium Salt (2:1)
|
Below are MeSH descriptors whose meaning is more general than "Valproic Acid".
Below are MeSH descriptors whose meaning is more specific than "Valproic Acid".
This graph shows the total number of publications written about "Valproic Acid" by people in this website by year, and whether "Valproic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 5 | 0 | 5 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Valproic Acid" by people in Profiles.
-
Lawal OD, Meador KJ, Hume AL, Wen X. Utilization of Antiseizure Medications in Women of Childbearing Age With Epilepsy and Nonepilepsy Indications: A Retrospective Cohort Study. Neurology. 2023 Sep 05; 101(10):e1083-e1096.
-
Smith EG, Austin KL, Kim HM, Miller DR, Sauer BC, Valenstein M. Suicide death over the first year of lithium versus valproate treatment in cohorts with and without bipolar disorder. J Psychiatr Res. 2022 03; 147:349-356.
-
Logan RW, Ozburn AR, Arey RN, Ketchesin KD, Winquist A, Crain A, Tobe BTD, Becker-Krail D, Jarpe MB, Xue X, Zong W, Huo Z, Parekh PK, Zhu X, Fitzgerald E, Zhang H, Oliver-Smith J, DePoy LM, Hildebrand MA, Snyder EY, Tseng GC, McClung CA. Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2. Mol Psychiatry. 2021 08; 26(8):4066-4084.
-
Stadelmaier R, Nasri H, Deutsch CK, Bauman M, Hunt A, Stodgell CJ, Adams J, Holmes LB. Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism. Birth Defects Res. 2017 Aug 15; 109(14):1134-1143.
-
Smith EG, Austin KL, Kim HM, Eisen SV, Kilbourne AM, Miller DR, Zivin K, Hannemann C, Sauer BC, Valenstein M. Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders. Br J Psychiatry. 2015 Jul; 207(1):55-63.
-
Smith EG, Austin KL, Kim HM, Miller DR, Eisen SV, Christiansen CL, Kilbourne AM, Sauer BC, McCarthy JF, Valenstein M. Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: a historical prospective cohort study. BMC Psychiatry. 2014 Dec 17; 14:357.
-
Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014 Apr; 34(2):244-55.
-
Cassidy MR, Sherburne AC, Sheldon HK, Gainsbury ML, Heydrick S, Stucchi AF. Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways. Surgery. 2014 Feb; 155(2):234-44.
-
Singh S. Valproate use during pregnancy was linked to autism spectrum disorder and childhood autism in offspring. Ann Intern Med. 2013 Aug 20; 159(4):JC13.
-
Hasan A, Mitchell A, Schneider A, Halene T, Akbarian S. Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. Eur Arch Psychiatry Clin Neurosci. 2013 Jun; 263(4):273-84.